Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Plasmonic response of aptamer-functionalized gold nanoparticles <i>via</i> target-induced aggregation for oxytetracycline detection.

Analytical methods : advancing methods and applications·2026
Same author

Sustainable metallic biomaterials for orthopaedic implants: a comprehensive review of biodegradable and conventional metals.

Biomedical materials (Bristol, England)·2026
Same author

Towards trustworthy brain stroke diagnosis using a lightweight explainable deep learning framework for CT imaging.

Scientific reports·2026
Same author

A Metal Importer and Exporter Interact Differently in the Chloroplast and Cell Membrane.

Membranes·2026
Same author

Smartphone interfaced image based creatinine estimation on a novel micro pipette tip-based platform: Whole blood sample-to-creatinine readout.

Analytica chimica acta·2026
Same author

Development of Bioisosteres of Iboga Alkaloids: A Step-Economical Synthesis to Enhance the Antinociceptive and Anxiolytic Activity with Neuroprotective Effects.

ACS pharmacology & translational science·2026

相关实验视频

Updated: May 10, 2026

Prehospital Thrombolysis: A Manual from Berlin
05:52

Prehospital Thrombolysis: A Manual from Berlin

Published on: November 27, 2013

常规使用特内克替的安全性和有效性在大型电脑电动电动网络中.

Arpan Dutta1, Arnab Sarkar2, Subhadeep Gupta1

  • 1Department of Neurology, Institute of Postgraduate Medical Education and Research, Kolkata, India.

The neurologist
|March 3, 2026
PubMed
概括

丁氏甲是一种安全有效的替代品Alteplase急性缺血性中风 (AIS) 管理. 这项研究发现,在大型电脑中风网络中,Tenecteplase和Alteplase之间的结果,出血或死亡率没有显著差异.

关键词:
另一个地方.缺血性中风 中风没有替代品.血栓溶解是一种血栓溶解.

更多相关视频

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

The Stroke Preclinical Assessment Network Multi-Laboratory Model of Thromboembolic Stroke with Thrombolysis: TE-MCAo
06:38

The Stroke Preclinical Assessment Network Multi-Laboratory Model of Thromboembolic Stroke with Thrombolysis: TE-MCAo

Published on: December 19, 2025

相关实验视频

Last Updated: May 10, 2026

Prehospital Thrombolysis: A Manual from Berlin
05:52

Prehospital Thrombolysis: A Manual from Berlin

Published on: November 27, 2013

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

The Stroke Preclinical Assessment Network Multi-Laboratory Model of Thromboembolic Stroke with Thrombolysis: TE-MCAo
06:38

The Stroke Preclinical Assessment Network Multi-Laboratory Model of Thromboembolic Stroke with Thrombolysis: TE-MCAo

Published on: December 19, 2025

科学领域:

  • 神经学 神经学
  • 心血管医学 心血管医学
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 丁氏甲是急性缺血性中风 (AIS) 的新兴血栓解压剂.
  • 证据表明,Tenecteplase在AIS管理中不劣于Alteplase.
  • 在大型血管封闭的情况下,Tenecteplase在成本,管理和再通道方面具有优势.

研究的目的:

  • 为了评估常规使用Tenecteplase的安全性和有效性,在一个大型的印度远程中风网络中进行了评估.
  • 为了比较Tenecteplase与Alteplase在患者的治疗结果和安全性方面.
  • 评估Tenecteplase在AIS管理中的实际数据.

主要方法:

  • 印度西孟加拉州Swasthya Ingit电脑中风计划中AIS患者的回顾性观察性研究 (2022年1月 - 2024年12月).
  • 患者接受Tenecteplase与Alteplase进行血栓溶解的比较.
  • 主要结局指标包括良好的功能结局 (修改的兰金尺度0-2在90天),症状内出血,和3个月的所有原因死亡率.

主要成果:

  • 分析了1526名患者;1389名患者接受了Tenecteplase,137名患者接受了Alteplase.
  • 在Tenecteplase使用和有利的结果之间没有发现显著的关联 (OR:1.03,P=0.93).
  • 甲的使用与症状性内出血 (OR:0.63,P=0.41) 或所有原因死亡率 (OR:0.54,P=0.15) 的增加无关.

结论:

  • 针对急性缺血性中风的常规Tenecteplase注射在现实临床实践中是安全和有效的.
  • 这项研究支持Tenecteplase作为在远程中风网络中对Alteplase的可行替代品.
  • 实际数据证实了Tenecteplase在AIS管理中的非劣势性和安全性.